Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/06/24 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
4 | |
| 06/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/04/24 | 8-K | Current report filing |
|
   |
3 |
| 05/15/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
110 |
| 05/15/24 | 8-K | Current report filing |
|
|
29 |
| 04/23/24 | ARS | Annual report to security holders |
|
160 |
